- Home
- LENZ vs PFLT Comparison
LENZ vs PFLT Comparison
Compare LENZ & PFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- PFLT
- Stock Information
- Founded
- LENZ 2019
- PFLT 2010
- Country
- LENZ United States
- PFLT United States
- Employees
- LENZ N/A
- PFLT N/A
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- PFLT Finance: Consumer Services
- Sector
- LENZ Health Care
- PFLT Finance
- Exchange
- LENZ Nasdaq
- PFLT Nasdaq
- Market Cap
- LENZ 795.5M
- PFLT 808.2M
- IPO Year
- LENZ 2021
- PFLT N/A
- Fundamental
- Price
- LENZ $26.34
- PFLT $10.08
- Analyst Decision
- LENZ Strong Buy
- PFLT Buy
- Analyst Count
- LENZ 5
- PFLT 4
- Target Price
- LENZ $41.80
- PFLT $11.38
- AVG Volume (30 Days)
- LENZ 259.1K
- PFLT 892.7K
- Earning Date
- LENZ 05-07-2025
- PFLT 05-12-2025
- Dividend Yield
- LENZ N/A
- PFLT 12.23%
- EPS Growth
- LENZ N/A
- PFLT 16.92
- EPS
- LENZ N/A
- PFLT 1.37
- Revenue
- LENZ N/A
- PFLT $215,391,000.00
- Revenue This Year
- LENZ N/A
- PFLT $48.14
- Revenue Next Year
- LENZ $544.90
- PFLT $9.03
- P/E Ratio
- LENZ N/A
- PFLT $7.36
- Revenue Growth
- LENZ N/A
- PFLT 47.56
- 52 Week Low
- LENZ $14.42
- PFLT $8.82
- 52 Week High
- LENZ $38.93
- PFLT $12.02
- Technical
- Relative Strength Index (RSI)
- LENZ 52.07
- PFLT 48.36
- Support Level
- LENZ $22.52
- PFLT $9.98
- Resistance Level
- LENZ $27.37
- PFLT $10.18
- Average True Range (ATR)
- LENZ 2.19
- PFLT 0.17
- MACD
- LENZ -0.14
- PFLT 0.06
- Stochastic Oscillator
- LENZ 47.99
- PFLT 79.49
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.